AU2018265541B2 - Viral vector production - Google Patents

Viral vector production Download PDF

Info

Publication number
AU2018265541B2
AU2018265541B2 AU2018265541A AU2018265541A AU2018265541B2 AU 2018265541 B2 AU2018265541 B2 AU 2018265541B2 AU 2018265541 A AU2018265541 A AU 2018265541A AU 2018265541 A AU2018265541 A AU 2018265541A AU 2018265541 B2 AU2018265541 B2 AU 2018265541B2
Authority
AU
Australia
Prior art keywords
transgene
amirna
cell
mammalian
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018265541A
Other languages
English (en)
Other versions
AU2018265541A1 (en
Inventor
Guangping Gao
Jun Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of AU2018265541A1 publication Critical patent/AU2018265541A1/en
Application granted granted Critical
Publication of AU2018265541B2 publication Critical patent/AU2018265541B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018265541A 2017-05-12 2018-05-11 Viral vector production Active AU2018265541B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505540P 2017-05-12 2017-05-12
US62/505,540 2017-05-12
PCT/US2018/032291 WO2018209216A1 (en) 2017-05-12 2018-05-11 Viral vector production

Publications (2)

Publication Number Publication Date
AU2018265541A1 AU2018265541A1 (en) 2019-12-05
AU2018265541B2 true AU2018265541B2 (en) 2023-05-25

Family

ID=64105048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018265541A Active AU2018265541B2 (en) 2017-05-12 2018-05-11 Viral vector production

Country Status (6)

Country Link
US (3) US11767539B2 (enExample)
EP (1) EP3621982A4 (enExample)
JP (1) JP2020519294A (enExample)
AU (1) AU2018265541B2 (enExample)
CA (1) CA3099990A1 (enExample)
WO (1) WO2018209216A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018265541B2 (en) 2017-05-12 2023-05-25 University Of Massachusetts Viral vector production
CN111433356B (zh) 2017-10-10 2023-12-19 南特生物科学公司 对病毒生产有效载荷具有低毒性的经修饰的ec7细胞
EP4352220A4 (en) * 2021-05-18 2025-09-24 Asimov Inc VIRAL VECTOR PRODUCTION SYSTEMS, CELLS MODIFIED FOR VIRAL VECTOR PRODUCTION AND METHODS OF USE THEREOF
WO2025153852A1 (en) * 2024-01-17 2025-07-24 1. Revvity Gene Delivery Gmbh Production of viral vectors
GB202401004D0 (en) * 2024-01-25 2024-03-13 Oxford Genetics Ltd Retroviral vectors
CN119662733B (zh) * 2024-12-09 2025-10-28 广州派真生物技术有限公司 一种高产rAAV的质粒系统及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2915124C (en) 2001-11-13 2018-08-14 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
PL2002003T3 (pl) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2017189901A1 (en) * 2016-04-27 2017-11-02 Baylor College Of Medicine Silencing transgene expression during vector production
AU2018265541B2 (en) 2017-05-12 2023-05-25 University Of Massachusetts Viral vector production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUN XIE ET AL: "772. RNA Interference Mediated Ablation of Cytotoxic Transgenes Enables Productive Viral Vector Packaging", MOLECULAR THERAPY, vol. 25, no. 5 Suppl.1, 1 May 2017, pages 357 - 358 *
PALMER, DJ ET AL.: "Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector", MOLECULAR THERAPY: METHODS AND CLINICAL DEVELOPMENT, vol. 3, 8 June 2016, No. 16039 *
REID, C. et al. "Micro-RNA induced silencing of cytotoxic transgenes leads to increased recombinant adeno-associated virus (AAV) titers", Investigative Ophthalmology & Visual Science, ARVO Annual Meeting Abstract, 2016, Vol. 57 *

Also Published As

Publication number Publication date
EP3621982A1 (en) 2020-03-18
EP3621982A4 (en) 2021-05-19
US20200199622A1 (en) 2020-06-25
WO2018209216A1 (en) 2018-11-15
JP2020519294A (ja) 2020-07-02
US12344857B2 (en) 2025-07-01
US11767539B2 (en) 2023-09-26
US20240035046A1 (en) 2024-02-01
CA3099990A1 (en) 2018-11-15
AU2018265541A1 (en) 2019-12-05
US20250346923A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
US12344857B2 (en) Viral vector production
US20250115880A1 (en) Viral vector production system
US12331296B2 (en) Variant RNAi
US20110207226A1 (en) Non-integrating lenti/adeno-associated virus hybrid vector system
WO2010113037A1 (en) Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
US11767530B2 (en) Splice inhibiting oligonucleotides
JP7759318B2 (ja) 産生系
KR20220035338A (ko) 렌티바이러스 벡터의 생산 향상
GB2545763A (en) Mutant viral capsid libraries and related systems and methods
KR20220154734A (ko) 렌티바이러스 벡터
KR20220139911A (ko) 렌티바이러스 벡터의 생산
EP4530355A2 (en) Lentiviral vectors
CN119546751A (zh) 改进的重组腺相关病毒生产方法
WO2023062359A2 (en) Novel viral regulatory elements
US20250188490A1 (en) Methods of raav packaging
CN117677706A (zh) 慢病毒载体
Yu et al. By Beverly L. Davidson and Scott Q. Harper

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)